Trial · NCT05011513
Results by group86
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 86
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Time to Sustained Alleviation of Overall COVID-19 Signs and Symptoms Through Day 28 | Nirmatrelvir 300 mg + Ritonavir 100 mg | 12.000 | 95% Confidence Interval 11.000 to 13.000 | Days | |
| Time to Sustained Alleviation of Overall COVID-19 Signs and Symptoms Through Day 28 | Placebo | 13.000 | 95% Confidence Interval 12.000 to 14.000 | Days | |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious AEs and AEs Leading to Study and Study Drug Discontinuation | Nirmatrelvir 300 mg + Ritonavir 100 mg | TEAEs | 169 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious AEs and AEs Leading to Study and Study Drug Discontinuation | Placebo | TEAEs | 153 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious AEs and AEs Leading to Study and Study Drug Discontinuation | Nirmatrelvir 300 mg + Ritonavir 100 mg | SAEs | 8 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious AEs and AEs Leading to Study and Study Drug Discontinuation | Placebo | SAEs | 13 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious AEs and AEs Leading to Study and Study Drug Discontinuation | Nirmatrelvir 300 mg + Ritonavir 100 mg | AEs led to discontinuation of study | 0 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious AEs and AEs Leading to Study and Study Drug Discontinuation | Placebo | AEs led to discontinuation of study | 1 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious AEs and AEs Leading to Study and Study Drug Discontinuation | Nirmatrelvir 300 mg + Ritonavir 100 mg | AEs led to discontinue study intervention and continued study | 16 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious AEs and AEs Leading to Study and Study Drug Discontinuation | Placebo | AEs led to discontinue study intervention and continued study | 5 | Participants | |
| Percentage of Participants With COVID-19 Related Hospitalization or Death From Any Cause Through Day 28 | Nirmatrelvir 300 mg + Ritonavir 100 mg | COVID-19 hospitalization | 0.765 | Percentage of participants | |
| Percentage of Participants With COVID-19 Related Hospitalization or Death From Any Cause Through Day 28 | Placebo | COVID-19 hospitalization | 1.577 | Percentage of participants | |
| Percentage of Participants With COVID-19 Related Hospitalization or Death From Any Cause Through Day 28 | Nirmatrelvir 300 mg + Ritonavir 100 mg | Death | 0 | Percentage of participants | |
| Percentage of Participants With COVID-19 Related Hospitalization or Death From Any Cause Through Day 28 | Placebo | Death | 0.158 | Percentage of participants | |
| Percentage of Participants With Death Through Week 24 | Nirmatrelvir 300 mg + Ritonavir 100 mg | 0 | Percentage of participants | ||
| Percentage of Participants With Death Through Week 24 | Placebo | 0.2 | Percentage of participants | ||
| Number of COVID-19 Related Medical Visits Per Day Through Day 28 | Nirmatrelvir 300 mg + Ritonavir 100 mg | 0.0010 | 95% Confidence Interval 0.0005 to 0.0019 | Medical visits per day | |
| Number of COVID-19 Related Medical Visits Per Day Through Day 28 | Placebo | 0.0020 | 95% Confidence Interval 0.0010 to 0.0038 | Medical visits per day | |
| Duration of Hospitalization and Intensive Care Unit (ICU) Stay Through Day 28 | Nirmatrelvir 300 mg + Ritonavir 100 mg | Hospitalization | 0.049 | Standard Deviation 0.591 | Days |
| Duration of Hospitalization and Intensive Care Unit (ICU) Stay Through Day 28 | Placebo | Hospitalization | 0.181 | Standard Deviation 1.787 | Days |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05011513/results